Acquired hemophilia: a case report and review of the literature

@article{Mulliez2014AcquiredHA,
  title={Acquired hemophilia: a case report and review of the literature},
  author={S. Mulliez and A. Vantilborgh and K. Devreese},
  journal={International Journal of Laboratory Hematology},
  year={2014},
  volume={36}
}
Acquired hemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against clotting factor VIII (FVIII). FVIII autoantibody is characterized as polyclonal immunoglobulin G directed against the FVIII procoagulant activity. This disease occurs most commonly in the elderly population and with preponderance of men in nonpregnancy‐related AHA. There are well‐established clinical associations with AHA such as malignancy, other autoimmune diseases and pregnancy. However, up to 50% of… Expand
Acquired Hemophilia in a Patient With Rheumatoid Arthritis: Case Report and Literature Review
TLDR
35 cases of acquired hemophilia A with hemarthroses were found, 35 in systemic lupus erythematosus and 12 in rheumatoid arthritis, while the remaining cases were reported in Sjogren’s syndrome, polymyalgia rheumatica, systemic sclerosis, and psoriatic arthritis. Expand
Acquired hemophilia A: when an overlooked autoimmune disorder causes significant bleeding
TLDR
Optimal management of AHA necessitates a multidisciplinary approach in collaboration between hematologists and physicians from various specialties, as well as a review of the literature in order to better understand the disease. Expand
Postpartum Acquired Hemophilia A: Case Report and Literature Review
TLDR
The authors report a case of Acquired Hemophilia A associated with pregnancy with several muco-cutaneous hemorrhagic manifestations and intramuscular hematomas with excellent response to the use of immunosuppressants. Expand
Acquired Hemophilia Secondary to Soft-tissue Sarcoma: Case Report from a Latin American Hospital and Literature Review
TLDR
A 52-year-old male with back myxofibrosarcoma who developed acquired hemophilia without response to treatment used and ultimately died, limiting the treatment to immunosuppressive and “bypass” management. Expand
Targeting Acquired Hemophilia A with Rheumatoid Arthritis by a Rituximab Shot: A Case Report and Review of the Literature
TLDR
Rituximab remains a relevant alternative for managing simultaneous AH with inhibitor and RA, and the reappearance of the anti-factor VIII inhibitor was found, thus justifying a second cycle of ritUXimab. Expand
Acquired Hemophilia A: A Case Report
TLDR
This case report summarizes the successful treatment of a patient with acquired hemophilia A and major bleeding following a surgical procedure, with the use of desmopressin, recombinant factor VIIa, repeated doses of recombinantfactor VIII, rituximab, and prednisone. Expand
Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges.
TLDR
The diagnostic approach to AHA is reviewed, assay-specific limitations are discussed and some of the challenges for future research are addressed, including why laboratory data failed to predict bleeding or response to treatment in AHA. Expand
Acquired Hemophilia A Presenting as Massive Postoperative Bleeding in a Patient with Oral Squamous Cell Carcinoma
TLDR
This case indicates that AHA should not be ruled out in patients with uncontrolled postoperative bleeding, while attempting to ensure bleeding control and preventing potentially catastrophic fatal consequences. Expand
Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung disease
TLDR
The patient matches the typical elderly male demographic of AHA and his relapsing course with remarkably high and persistent inhibitor titre highlights the need for close monitoring and aggressive upfront treatment. Expand
Importancia de la orientación diagnóstica en hemofilia A adquirida
TLDR
The importance of adequate screening in patients with suspected AHA to make an adequate diagnosis and reduce overall fatal outcomes is highlighted. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 73 REFERENCES
Acquired hemophilia in pediatrics: A systematic review
TLDR
The management of acute bleeding and the inhibitor eradication are the mainstay of the treatment and the outcome in pediatric patients seems more favorable than in adults because the inhibitors usually resolve more quickly and in a higher rate of patients. Expand
Consensus recommendations for the diagnosis and treatment of acquired hemophilia A
TLDR
Recommendations aim to increase awareness of this disorder among clinicians in a wide range of specialties and provide practical advice on diagnosis and treatment of acquired hemophilia A. Expand
International recommendations on the diagnosis and treatment of patients with acquired hemophilia A
TLDR
Treatment guidance for acquired hemophilia A is provided, based on collective clinical experience in treating patients with AHA, to contribute to improved care for this patient group. Expand
Drug-induced anti-factor VIII antibodies: a systematic review.
  • M. Franchini, F. Capra, +4 authors G. Lippi
  • Medicine
  • Medical science monitor : international medical journal of experimental and clinical research
  • 2007
TLDR
Although most inhibitors reported in the literature were at high titers, their prognosis was good, as they disappeared in most cases after suspension of the involved drug or after immunosuppressive therapy, further studies are needed to better elucidate the epidemiology, natural history, clinical relevance, and optimal treatment of drug-associated factor VIII autoantibodies. Expand
Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.
TLDR
This report summarizes the experience related to AH from a large Australian hemophilia center based in South Australia and reviews diagnostic features, treatment for bleeds and to eradicate the autoantibody, treatment response, and survival outcomes. Expand
Laboratory, clinical and therapeutic aspects of acquired hemophilia A.
TLDR
This review focuses on the most recent advances in the treatment of acquired hemophilia A, which is primarily aimed to control bleeding episodes and to eradicate the autoantibody production. Expand
Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.
TLDR
The modified Bonn-Malmo Protocol for acquired hemophilia included immunoadsorption for inhibitor elimination, factor VIII substitution, intravenous immunoglobulin, and immunosuppression, and showed an overall response rate of 88% for complete remission (CR). Expand
Diagnosis and treatment of acquired haemophilia
TLDR
Acquired haemophilia is an autoimmune syndrome characterized by acute bleeding in patients with negative family and personal history, and factor VIII depletion, which is associated with autoimmune diseases, solid tumours, lymphoprolipherative diseases, pregnancy. Expand
Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors
TLDR
A succinct review of the clinical features, laboratory diagnosis, prognostic factors and therapeutic management of patients with acquired haemophilia is provided. Expand
Single‐center experience with rituximab as first‐line immunosuppression for acquired hemophilia
Acquired hemophilia (AH) is a rare, life-threatening bleeding disorder with an estimated incidence of 1.48 patients per million per year and a median age at presentation of 78 years [1]. It is causedExpand
...
1
2
3
4
5
...